We are live on ! Find out more
BBA

Baker Bros. Advisors Portfolio holdings

AUM $17.4B
1-Year Est. Return 131.5%
This Fund
S&P 500
This Quarter Est. Return
+12.37%
1 Year Est. Return
+131.5%
3 Year Est. Return
+336.81%
5 Year Est. Return
+553.16%
10 Year Est. Return
+4,134.93%
AUM
$7.87B
AUM Growth
+$772M
Cap. Flow
-$1.35B
Cap. Flow %
-17.14%
Top 10 Hldgs %
73.35%
Holding
114
New
19
Increased
20
Reduced
44
Closed
6

Top Buys

Rank Stock Value
1
ITMN
INTERMUNE INC
ITMN
+$93M
2
GEVA
SYNAGEVA BIOPHARMA CORP COM STK (DE)
GEVA
+$34.7M
3
ACOR
Acorda Therapeutics
ACOR
+$33.7M
4
HRTX icon
Heron Therapeutics
HRTX
+$29M
5
XNPT
XENOPORT, INC.
XNPT
+$18.1M

Top Sells

Rank Stock Value
1
ARWR icon
Arrowhead Research
ARWR
+$41.4M
2
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
+$35.9M
3
MDVN
MEDIVATION, INC.
MDVN
+$25.4M
4
HALO icon
Halozyme
HALO
+$8.89M
5
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$8.88M

Sector Composition

Rank Sector Weight
1 Healthcare 43.43%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DYAX
26
DELISTED
DYAX CORPORATION
DYAX
$22.7M 0.29%
2,531,766
+505,229
+25% +$4.59M
AVNR
27
DELISTED
AVANIR PHARMACEUTICALS, INC CL A
AVNR
$21.3M 0.27%
5,790,139
+361,548
+7% +$1.38M
XNPT
28
DELISTED
XENOPORT, INC.
XNPT
$20.9M 0.27%
4,034,112
+3,000,000
+290% +$18.1M
PGNX
29
DELISTED
Progenics Pharmaceuticals Inc
PGNX
$18.2M 0.23%
4,449,797
+249,797
+6% +$1.28M
NGNE icon
30
Neurogene
NGNE
$648M
$15.4M 0.2%
+60,593
New +$15.6M
TGTX icon
31
TG Therapeutics
TGTX
$8.17B
$14.9M 0.19%
2,160,965
-38,691
-2% -$229K
KYTH
32
DELISTED
KYTHERA BIOPHARMACEUTICALS, INC COM
KYTH
$12.4M 0.16%
311,255
-1,936
-0.6% -$86.6K
ARWR icon
33
Arrowhead Research
ARWR
$11.9B
$12M 0.15%
732,062
-2,357,938
-76% -$41.4M
INSM icon
34
Insmed
INSM
$22.6B
$10.5M 0.13%
554,050
-242,328
-30% -$4.61M
ABUS icon
35
Arbutus Biopharma
ABUS
$845M
$10.4M 0.13%
484,156
-15,844
-3% -$285K
SGMO
36
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$9.45M 0.12%
522,764
+98,456
+23% +$1.9M
SGYP
37
DELISTED
Synergy Pharmaceuticals, Inc Common Stock
SGYP
$9.34M 0.12%
1,758,271
-886,516
-34% -$4.97M
OMER icon
38
Omeros
OMER
$826M
$9.1M 0.12%
753,804
+145,400
+24% +$1.79M
PRTA icon
39
Prothena Corp
PRTA
$441M
$8.82M 0.11%
230,142
-106,776
-32% -$3.44M
MTEM
40
DELISTED
Molecular Templates, Inc.
MTEM
$8.69M 0.11%
11,069
-158
-1% -$128K
QLTI
41
DELISTED
QLT Inc
QLTI
$8.54M 0.11%
1,535,863
– –
WINT
42
DELISTED
Windtree Therapeutics Inc
WINT
$7.85M 0.1%
260,866
-4,750
-2% -$160K
AGIO icon
43
Agios Pharmaceuticals
AGIO
$2.08B
$7.83M 0.1%
199,893
-5,857
-3% -$196K
GALT icon
44
Galectin Therapeutics
GALT
$225M
$7.66M 0.1%
500,000
+399,400
+397% +$5.69M
INFI
45
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
$7.42M 0.09%
+624,050
New +$8.37M
NBIX icon
46
Neurocrine Biosciences
NBIX
$18.2B
$7.21M 0.09%
+447,874
New +$7.66M
STML
47
DELISTED
Stemline Therapeutics, Inc.
STML
$6.89M 0.09%
338,671
-336,371
-50% -$8.16M
AMBI
48
DELISTED
Ambit Biosciences Corp
AMBI
$6.82M 0.09%
747,954
– –
VXRT
49
DELISTED
Vaxart
VXRT
$6.76M 0.09%
100,628
-2,110
-2% -$130K
ARRY
50
DELISTED
Array Biopharma Inc
ARRY
$6.74M 0.09%
1,433,797
-66,203
-4% -$333K
1
2
3 4

Similar funds

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
BCIM
British Columbia Investment Management Victoria, British Columbia, Canada $17B AUM 31.69% 1-Year Est. Return

Baker Bros. Advisors's Q1 2014 Portfolio in Review

As of Q1 2014, Baker Bros. Advisors held 114 positions worth $7.87B, up 11% from $7.1B the previous quarter. Its ten largest holdings account for 73% of the portfolio.

Baker Bros. Advisors withdrew a net $1.35B in Q1 2014, closing 6 positions and reducing 44 holdings. Its most notable exit was MEDIVATION, INC., an estimated $25.4M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 43% of assets, down from 44% a quarter earlier.

Against the trend, Baker Bros. Advisors opened a new position in Acorda Therapeutics worth $37.9M.

  • Baker Bros. Advisors's largest Q1 2014 buy was Acorda Therapeutics: 8,333 shares worth $37.9M.
  • Baker Bros. Advisors added most to INTERMUNE INC in Q1 2014, an estimated $93M increase.
  • Baker Bros. Advisors's biggest Q1 2014 reduction was Arrowhead Research, cutting an estimated $41.4M.
  • Baker Bros. Advisors fully exited MEDIVATION, INC. in Q1 2014, selling an estimated $25.4M.
  • Baker Bros. Advisors's ten largest holdings make up 73% of its $7.87B portfolio in Q1 2014.
  • Baker Bros. Advisors opened 19 new positions and closed 6 in Q1 2014.
  • Baker Bros. Advisors's portfolio value rose 11% quarter-over-quarter to $7.87B.

Based on Baker Bros. Advisors's 13F filing for Q1 2014, filed 15 May 2014.